<DOC>
	<DOCNO>NCT01592110</DOCNO>
	<brief_summary>This Phase 1 , open-label study evaluate safety pharmacokinetics ( PK ) three dose risperidone-SABER , administer needle syringe via DosePro Needle-Free Delivery System patient chronic , stable schizophrenia .</brief_summary>
	<brief_title>A Safety PK Study Injectable Risperidone-SABER DosePro Delivery System Patients With Schizophrenia</brief_title>
	<detailed_description>This open-label , single ascend dose ( SAD ) , safety PK study patient chronic , stable schizophrenia schizoaffective disorder . Patients participate study total 10 week Cohorts 1-3 , include Screening period 35 day study treatment period 35 day , 14 week Cohort 4 , include Screening period 35 day study treatment period 63 day . Patients assign one four cohort , receive single dose 25 mg , 50 mg 100 mg ( 100 mg/mL concentration ) administer single subcutaneous ( SC ) injection via DosePro Needle-Free Delivery System .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male female patient 18 year age old . Diagnosis schizophrenia , schizoaffective disorder , schizophreniform disorder per DSMIV criterion past 6 month , dependent diagnosis . Currently maintenance antipsychotic medication ( i.e. , patient treat antipsychotic medication stable dose 4 week prior Screening psychosisrelated dose change 8 week prior Screening ) . Body Mass Index ( BMI ) ( kg/m2 ) ≥ 20 ≤ 40 . Female patient : Nonchildbearing potential ( surgically sterile [ hysterectomy ] ) postmenopausal ≥ 2 year OR Nonpregnant , nonlactating female childbearing potential agree use medically acceptable form birth control ( hormonal contraception , abstinence , diaphragm spermicide , condom spermicide , intrauterine device ) Screening EndofStudy visit . No clinically significant abnormal laboratory value . No clinically significant finding 12lead electrocardiogram ( ECG ) . No clinically significant finding vital sign measurement . Be informed nature study give write consent prior initiate study procedure . Have know suspected carcinoma . Have know presence history renal hepatic insufficiency . Have know history , hypersensitivity idiosyncratic reaction ( include dystonias ) risperidone , paliperidone , and/or drug substance similar activity . Have history alcohol drugdependence per DSMIV criterion 6month period immediately prior Screening . Have history epilepsy risk seizure . Are pregnant , lactating , likely become pregnant study . Have take antipsychotic depot product ( include investigational product ) within 60 day prior Screening . Participated another clinical trial receive investigational product within 30 day prior Screening . Have positive alcohol breathalyzer test Screening Admission . Have positive Screening test hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) . Have positive urine drug test ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids , etc . ) Screening Admission . Excessive use caffeinecontaining beverage exceed 500 mg caffeine/day ( 5 cup coffee ) . Are unwilling avoid use alcohol alcoholcontaining food , medication beverage , within 48 hour prior Admission EndofStudy . Excessive smoking judge Investigator Donation blood ( &gt; 500 mL ) blood product within 2 month ( 56 day ) prior Admission . Have use concomitant medication significantly impact CYP2D6 ( moderate strong inducers/inhibitors ) , include limited outline Appendix 1 , within 14 day 5 halflives ( whichever longer ) prior Admission . Medications judge interact risperidone may continue discretion Investigator accordance protocol requirement taper washout . Are unwilling abstain vigorous exercise ( judged Investigator ) 48 hour prior Admission EndofStudy . Are unable understand protocol requirement , instruction study relate restriction , nature , scope possible consequence clinical study . Are unlikely comply protocol requirement , instruction study relate restriction ( e.g. , uncooperative attitude , inability return outpatient visit improbability complete clinical study ) . Have previously enrol clinical study . Are unable tolerate oral risperidone challenge Screening Day 3 . Are unable stabilize antipsychotic medication taper Screening period . Note `` Admission '' criterion refers Admission Qualification occur day 4 Cohort 1 Day 6 Cohorts 2 3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>